Acurx Pharmaceuticals, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting companyEmerging growth company
State of Incorporation
DE
Business Address
259 LIBERTY AVENUE, STATEN ISLAND, NY, 10305
Mailing Address
259 LIBERTY AVENUE, STATEN ISLAND, NY, 10305
Phone
917-533-1469
Fiscal Year End
1231
EIN
000000000
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-K Annual financial report | March 12, 2026 | View on SEC |
| 8-K Current report of material events | March 9, 2026 | View on SEC |
| S-1 IPO registration statement | February 2, 2026 | View on SEC |
| S-3/A Shelf registration amendment | December 30, 2025 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | November 14, 2025 | View on SEC |
| 10-Q Quarterly financial report | November 12, 2025 | View on SEC |
| S-1 IPO registration statement | October 20, 2025 | View on SEC |
| 8-K Current report of material events | September 22, 2025 | View on SEC |
| 8-K Current report of material events | September 19, 2025 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | August 14, 2025 | View on SEC |
Annual Reports
10-K
March 12, 2026
- Ibezapolstat Phase 2b clinical trial successfully completed with positive safety and high sustained clinical response rates.
- Engaged in discussions with the FDA for the design of a pivotal Phase 3 program for ibezapolstat.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.